Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Multi-analyte liquid biopsy to monitor tumor genomic evolution and therapy response in advanced Prostate Cancer

Project description

An exosome-based liquid biopsy for prostate cancer

Exosomes are small vesicles secreted by the majority of eukaryotic cells and contain proteins, DNA and other biomolecules. Emerging evidence indicates that cancer cells also secrete exosomes which can be exploited as an approach for cancer diagnosis. MultiLQB-PC is an EU-funded project that aims to develop a liquid biopsy-based approach for the non-invasive diagnosis of prostate cancer. Researchers will integrate the detection of circulating tumour DNA and circulating tumour cells with exosomes to generate a sensitive assay for monitoring the progression of metastatic prostate cancer. MultiLQB-PC is expected to also aid disease prognosis and patient stratification and identify drug resistance cases.

Objective

Metastatic prostate cancer (mPC) is a lethal disease. Androgen deprivation therapy is the mainstay of patient care. In addition, DNA repair defects is a novel therapeutic target in mPC. However, resistances invariably arise, triggered most of the times by tumor genomic evolution. Liquid biopsy has emerged as a tool to non-invasively profile tumor genomics over time. Beyond circulating tumor DNA (ctDNA) and circulating tumor cells (CTC), small extracellular vesicles, known as exosomes, have been identified to contain tumor genomic material. Over the last years, I have developed a method to pursue analysis of tumor genomic material from exosomes at a very low cost. The analysis of exoDNA/RNA is a promising tool that represents a new non-invasive, sensitive and very informative new method for PC monitoring.
In this project, I aim to integrate the genomic analysis of exoDNA/RNA together with ctDNA and CTCs in advanced PC to:1) Identify prognostic signatures for clinically-relevant patient stratification; 2) Define circulating predictive signatures of drug response/resistance; and 3) Validate biomarkers of therapy response for selection of subsequent lines of treatment.
Therefore, this fellowship would allow me to take a significant step towards the implementation of this new technology in the study of mPC genomics and mechanisms of response/resistance to novel targeted drugs. Furthermore, I will be able to integrate my research into clinical trials and, ultimately, impact personalized patient care.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2020

See all projects funded under this call

Coordinator

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Net EU contribution
€ 172 932,48
Address
CALLE NAZARET 115-117
08035 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 172 932,48